Allarity Therapeutics (ALLR) Competitors $0.78 -0.04 (-4.93%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. ELEV, NXTC, GLYC, BCTX, CARM, COCP, SLGL, MEIP, IMNN, and SYBXShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Elevation Oncology (ELEV), NextCure (NXTC), GlycoMimetics (GLYC), BriaCell Therapeutics (BCTX), Carisma Therapeutics (CARM), Cocrystal Pharma (COCP), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Imunon (IMNN), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Elevation Oncology NextCure GlycoMimetics BriaCell Therapeutics Carisma Therapeutics Cocrystal Pharma Sol-Gel Technologies MEI Pharma Imunon Synlogic Allarity Therapeutics (NASDAQ:ALLR) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the MarketBeat Community favor ALLR or ELEV? Elevation Oncology received 38 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 66.10% of users gave Elevation Oncology an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Elevation OncologyOutperform Votes3966.10% Underperform Votes2033.90% Does the media prefer ALLR or ELEV? In the previous week, Allarity Therapeutics had 3 more articles in the media than Elevation Oncology. MarketBeat recorded 3 mentions for Allarity Therapeutics and 0 mentions for Elevation Oncology. Allarity Therapeutics' average media sentiment score of 0.33 beat Elevation Oncology's score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Allarity Therapeutics Neutral Elevation Oncology Neutral Do insiders and institutionals believe in ALLR or ELEV? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ALLR or ELEV? Elevation Oncology has a consensus target price of $3.39, indicating a potential upside of 1,316.62%. Given Elevation Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Elevation Oncology is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elevation Oncology 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Which has stronger earnings & valuation, ALLR or ELEV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/AElevation OncologyN/AN/A-$45.70M-$0.81-0.30 Which has more risk and volatility, ALLR or ELEV? Allarity Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Is ALLR or ELEV more profitable? Elevation Oncology's return on equity of -59.73% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% Elevation Oncology N/A -59.73%-40.05% SummaryElevation Oncology beats Allarity Therapeutics on 10 of the 13 factors compared between the two stocks. Remove Ads Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.45M$6.56B$5.40B$7.28BDividend YieldN/A2.85%4.87%4.05%P/E RatioN/A6.8522.8817.61Price / SalesN/A194.91357.3086.64Price / CashN/A65.6738.1634.64Price / Book0.005.746.323.86Net Income-$11.90M$142.37M$3.21B$247.18M7 Day Performance-24.90%-9.71%-6.89%-6.27%1 Month Performance-13.22%-12.66%-1.87%-8.87%1 Year Performance-99.47%-16.65%4.62%-6.18% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics0.6184 of 5 stars$0.78-4.9%N/A-99.4%$3.45MN/A0.0010Gap UpELEVElevation Oncology2.074 of 5 stars$0.29-3.4%$3.39+1,067.5%-95.0%$17.17MN/A-0.3540Gap DownNXTCNextCure4.0222 of 5 stars$0.61+6.8%$3.50+474.7%-83.5%$17.06MN/A-0.2990News CoverageGap DownGLYCGlycoMimetics1.2617 of 5 stars$0.26-2.3%$8.00+2,933.8%-93.3%$17.01M$10,000.000.0050News CoverageBCTXBriaCell Therapeutics1.1918 of 5 stars$4.46-0.2%$32.00+617.5%-91.9%$16.54MN/A-0.338News CoverageGap DownCARMCarisma Therapeutics2.8971 of 5 stars$0.39-4.8%$4.94+1,154.8%-90.2%$16.44M$20.27M-0.2520Upcoming EarningsAnalyst ForecastNews CoverageGap DownCOCPCocrystal Pharma3.1313 of 5 stars$1.58+1.3%$7.00+343.0%-2.8%$16.08MN/A-0.8510Analyst RevisionNews CoveragePositive NewsGap DownSLGLSol-Gel Technologies2.6159 of 5 stars$0.57+9.7%$5.00+776.6%-52.4%$15.89M$11.71M-1.6850Positive NewsGap DownMEIPMEI Pharma3.7868 of 5 stars$2.35+2.2%$7.00+197.9%-47.4%$15.66M$65.30M-0.41100Gap DownIMNNImunon1.8415 of 5 stars$1.07+12.1%$20.50+1,824.9%-28.1%$15.57M$500,000.00-0.5630SYBXSynlogicN/A$1.29-0.7%N/A-35.2%$15.10M$8,000.00-0.3180 Remove Ads Related Companies and Tools Related Companies Elevation Oncology Alternatives NextCure Alternatives GlycoMimetics Alternatives BriaCell Therapeutics Alternatives Carisma Therapeutics Alternatives Cocrystal Pharma Alternatives Sol-Gel Technologies Alternatives MEI Pharma Alternatives Imunon Alternatives Synlogic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
